Walker Luke Nathaniel
Insider CIK 1701440 · CASC SVP, Clinical Development · HARP Chief Medical Officer · ZNTL Director · CNTX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics Inc. | A Award deriv | 2026-06-24 | 2026-06-26 | 45,000 | — | $0 | 45,000 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2026-06-16 | 2026-06-18 | 57,100 | — | $0 | 201,384 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2025-06-17 | 2025-06-18 | 57,603 | — | $0 | 144,284 | SEC↗ |
| CNTX Context Therapeutics Inc. | A Award deriv | 2025-06-12 | 2025-06-12 | 123,500 | — | $0 | 123,500 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | P Buy | 2025-01-31 | 2025-02-04 | 14,200 | $1.76 | $25.0K | 86,681 | SEC↗ |
| CNTX Context Therapeutics Inc. | A Award deriv | 2024-09-04 | 2024-09-05 | 19,315 | — | $0 | 19,315 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2024-05-24 | 2024-05-29 | 72,481 | — | $0 | 72,481 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | D To issuer deriv | 2024-03-11 | 2024-03-11 | 30,500 | — | $0 | 0 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | D To issuer deriv | 2024-03-11 | 2024-03-11 | 10,000 | — | $0 | 0 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | D To issuer | 2024-03-11 | 2024-03-11 | 135,000 | — | $0 | 0 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | A Award | 2024-01-07 | 2024-01-09 | 115,000 | — | $0 | 135,000 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | A Award | 2023-11-26 | 2023-11-28 | 20,000 | — | $0 | 20,000 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | A Award deriv | 2023-01-24 | 2023-01-26 | 100,000 | — | $0 | 100,000 | SEC↗ |
| HARP Harpoon Therapeutics, Inc. | A Award deriv | 2022-10-03 | 2022-10-04 | 305,000 | — | $0 | 305,000 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 334 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 2,500 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 1,250 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 2,500 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 1,250 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 5,834 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 8,334 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 130,000 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 12,000 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 7,800 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 50,000 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 35,100 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | D To issuer deriv | 2018-03-09 | 2018-03-13 | 20,834 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | U Tender | 2018-03-09 | 2018-03-13 | 10,315 | — | $0 | 0 | SEC↗ |
| CASC Cascadian Therapeutics, In | A Award deriv | 2018-02-01 | 2018-02-02 | 130,000 | — | $0 | 130,000 | SEC↗ |
| CASC Cascadian Therapeutics, In | M Exercise deriv | 2018-01-11 | 2018-01-16 | 1,950 | — | $0 | 5,850 | SEC↗ |
| CASC Cascadian Therapeutics, In | F Tax w/h | 2018-01-11 | 2018-01-16 | 637 | $3.92 | $2.5K | 5,303 | SEC↗ |
| CASC Cascadian Therapeutics, In | M Exercise | 2018-01-11 | 2018-01-16 | 1,950 | — | $0 | 5,940 | SEC↗ |
| CASC Cascadian Therapeutics, In | A Award deriv | 2017-09-18 | 2017-09-20 | 12,000 | — | $0 | 12,000 | SEC↗ |
| CASC Cascadian Therapeutics, In | A Award deriv | 2017-09-18 | 2017-09-20 | 50,000 | — | $0 | 50,000 | SEC↗ |